Abstract Number: 2423 • 2015 ACR/ARHP Annual Meeting
An Open-Label Extension Study to Assess the Long-Term Safety and Clinical Benefit of Etanercept on Children and Adolescents with Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, or Psoriatic Arthritis: A 4-Year Update
Background/Purpose: A Phase 3b, open-label, multicenter study (CLIPPER; NCT00962741) demonstrated the efficacy of etanercept (ETN) in subjects with the extended oligoarticular (eo), enthesitis-related (ERA), and…Abstract Number: 1532 • 2014 ACR/ARHP Annual Meeting
Efficacy of the Subcutaneous Formulation of Abatacept/Orencia in Rheumatoid Arthritis, a Single-Center Italian Experience
Background/Purpose Abatacept is a selective T cell costimulation modulator indicated for moderately to severely active Rheumatoid Arthritis (RA). Since August 2013 is available in Italy…Abstract Number: 481 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of Etanercept in Rheumatoid Arthritis Patients over 75 Years Old
Background/Purpose Early introductions of biologics in early rheumatoid arthritis (RA) patients are well documented, but there are few reports of biologics use in established elderly…Abstract Number: 2611 • 2014 ACR/ARHP Annual Meeting
Short Term Efficacy of Tumor Necrosis Factor Inhibitors in Patients with non–radiographic Axial Spondylarthritis and ankylosing Spondylitis; Results from Turkbio Registry
Background/Purpose Axial spondylarthritis (AxSpA) has been proposed as an umbrella term for ankylosing spondylitis (AS) and non-radiographic (nr) AxSpA). This new concept makes diagnosis of…Abstract Number: 2478 • 2014 ACR/ARHP Annual Meeting
Analysis of the Clinical Sustained Response after Retreatment with a Lower Dose of Rituximab in Patients with Chronic Inflammatory Arthropathies
Background/Purpose: The dosage of rituximab (RTX) approved for the treatment of active rheumatoid arthritis (RA) is two intravenous (iv.) 1 g infusions, separated by two…Abstract Number: 1868 • 2014 ACR/ARHP Annual Meeting
Can DAS 28 at 3 Months after the 1st Biologic Therapy Predict Subsequent Sustainable Clinical Remission in Polyarticular Juvenile Idiopathic Arthritis Patients?
Background/Purpose: To avoid the progression of joint damage, early decision making is important in JIA patients who failed to achieve sustainable clinical remission by…Abstract Number: 2628 • 2013 ACR/ARHP Annual Meeting
Immunogenicity Of Infliximab Modulates Efficacy and Safety In Behcet’s Disease Patients With Uveitis
Background/Purpose: Infliximab (IFX) suppresses ocular attacks in Behcet’s disease (BD) with uveitis, resulting in favorable long-term visual prognosis. However, some patients had ocular attacks which…Abstract Number: 2384 • 2013 ACR/ARHP Annual Meeting
Variability In Patient Characteristics and Outcomes In Rheumatoid Arthritis Upon Infliximab Treatment Based On The Size Of Biologic Treatment Registry Site
Background/Purpose: Efficacy of TNFi agents in the management of rheumatoid arthritis (RA) has been demonstrated in numerous controlled clinical trials. Variations with respect to patient…Abstract Number: 1550 • 2013 ACR/ARHP Annual Meeting
Validation Of The Ankylosing Spondylitis Disease Activity Score and Effectiveness Of Infliximab In The Treatment Of Ankylosing Spondylitis Over 4 Years: The Canadian Experience
Background/Purpose: The efficacy of anti-TNF in the management of Ankylosing Spondylitis (AS) has been demonstrated in numerous controlled clinical trials. The objective of this study…Abstract Number: 1528 • 2013 ACR/ARHP Annual Meeting
Patient-Tailored Dose Reduction Of Tumor Necrosis Factor-Alpha Blocking Agents In Ankylosing Spondylitis Patients With Stable Low Disease Activity
Background/Purpose: Tumor necrosis factor-alpha (TNF-α) blocking agents are very effective in controlling inflammation and improving clinical assessments in patients with ankylosing spondylitis (AS). In view…Abstract Number: 1516 • 2013 ACR/ARHP Annual Meeting
Safety and Efficacy Of Etanercept In Early Non-Radiographic Axial Spondyloarthritis: A Randomized, Double-Blind, Placebo-Controlled Trial At 24 Weeks
Background/Purpose: Limited data are available on the efficacy of anti-TNF agents in non-radiographic axial spondyloarthritis (nr-axSpA). The objective of this analysis is to compare the…Abstract Number: 1476 • 2013 ACR/ARHP Annual Meeting
Effectiveness Of Etanercept In Elderly Patients With Rheumatoid Arthritis: A Single Center Retrospective Study
Background/Purpose: Biological drugs have dramatically improved the prognosis of rheumatoid arthritis (RA), especially in those with early disease. These patientsare often in younger age with fewer…Abstract Number: 1339 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Of Biologics Agents For Patients With Rheumatoid Arthritis and Hepatitis B Carrier
Background/Purpose: Biologics suppress hepatitis B virus (HBV) replication and play an important role in eradicating HBV by stimulating HBV-specific cytotoxic T-cell responses. We found that…Abstract Number: 856 • 2013 ACR/ARHP Annual Meeting
Cost-Effectiveness Of Urate Lowering Strategies For The Management Of Gout
Background/Purpose: The new 2012 ACR guidelines for the management of gout have provided updated recommendations; however, the employed method do not address the societal costs…Abstract Number: 426 • 2013 ACR/ARHP Annual Meeting
Characteristics of Protocol-Specified Responders/Non-Responders Treated With Etanercept Plus Methotrexate in Period 1 of the Prize Study
Background/Purpose: Although frequently effective, treatment with synthetic or biologic disease-modifying antirheumatic drugs (DMARDs) does not adequately control disease activity in all patients. Prompt identification of…